By Dengyuemed International Business Department For decades, global oncology treatments have relied primarily on traditional modalities such as small-molecule inhibitors, antibody therapies, and cell therapies. However, challenges such as drug resistance, undruggable targets, and ...Learn More

By: DengYue International Business DivisionTen years ago, China was known primarily as a supplier of APIs and low-cost generic medicines to the world. Today, if someone tells you that China is developing, manufacturing, and exporting world-class oncology drugs, biologics, ...Learn More

No campo da biotecnologia e da biologia molecular, a integridade dos produtos farmacêuticos é fundamental, impactando diretamente os resultados de pesquisas, ensaios clínicos e a saúde pública. Embora o quadro regulatório da China para medicamentos tenha avançado ...Learn More

Author: DengYueMed International Business DepartmentIn October 2022, China’s first-in-class innovative drug, Dorzagliatin tablets (Huātángníng®), (INN, sometimes also called Dorzagidn) was approved by the National Medical Products Administration (NMPA) and included in the ...Learn More